Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001140361-25-003661
Filing Date
2025-02-10
Accepted
2025-02-10 10:16:19
Documents
78
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q ef20039028_10q.htm   iXBRL 10-Q 2881521
2 EXHIBIT 31.1 ef20039028_ex31-1.htm EX-31.1 11778
3 EXHIBIT 31.2 ef20039028_ex31-2.htm EX-31.2 11946
4 EXHIBIT 32.1 ef20039028_ex32-1.htm EX-32.1 5089
5 EXHIBIT 32.2 ef20039028_ex32-2.htm EX-32.2 5115
  Complete submission text file 0001140361-25-003661.txt   10511149

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA roiv-20241231.xsd EX-101.SCH 77793
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE roiv-20241231_cal.xml EX-101.CAL 92625
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE roiv-20241231_def.xml EX-101.DEF 381158
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20241231_lab.xml EX-101.LAB 975704
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20241231_pre.xml EX-101.PRE 554265
81 EXTRACTED XBRL INSTANCE DOCUMENT ef20039028_10q_htm.xml XML 1501431
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 001-40782 | Film No.: 25604082
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)